The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.
The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.
The conference will focus on new data on chemotherapy, hormonal therapy, and other aspects of treatment that have emerged over the past decade since the last consensus conference, and will culminate in the formulation of recommendations for clinical practice.
During the conference, a panel of experts (from outside of the NIH) will hear presentations from leading researchers and then consider questions on specific topics, such as the selection of chemotherapy, radiation therapy, and hormonal therapy. The agenda will also include the clinical use of prognostic markers and quality-of-life issues. Both node-negative and node-positive breast cancers will be discussed.
Health professionals, researchers, patient advocates, and other members of the public may register to attend the by sending an e-mail to breastcancer@prospectassoc.com or by going to the NIH web site for consensus conferences found at http://odp.od.nih.gov/consensus. Additional information is available by calling (301) 592-3320.
Gedatolisib Combo With/Without Palbociclib May Be New SOC in PIK3CA Wild-Type Breast Cancer
December 21st 2025“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.